Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150448 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
NCT01150448 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 212 participants.
The verdict
NCT01150448, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone palmitate 150 mg eq.
Interventions
- DRUG Paliperidone palmitate Treatment A
- DRUG Paliperidone palmitate Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150448
The ClinicalTrials.gov registry entry for NCT01150448 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paliperidone palmitate Treatment A is the first listed.
NCT01150448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150448 about?
NCT01150448 is a clinical study titled "A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia". The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone p...
What is the current status of trial NCT01150448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2007-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT01150448?
The interventions under investigation include: Paliperidone palmitate Treatment A (DRUG), Paliperidone palmitate Treatment B (DRUG).
Who is sponsoring clinical trial NCT01150448?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.